Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
Clinical trial NCT05121714 · COMPLETED
Trial details
- NCT number
- NCT05121714
- Sponsor
- Abivax S.A.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-17
- Primary completion
- 2021-05-18
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.